PAO Group, Inc.: PAOG Targets International Segment of $5 Billion CBD Nutraceutical Market
Sandusky, Ohio (Newsfile Corp. - May 13, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today revealed it will include foreign sales in the planned Q4 launch of its three CBD Nutraceutical Products.
The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion and it is expected to reach $16.4 Billion by 2027.
That market value represents global sales. PAOG management is targeting specific international segments to be included in its Q4 sales launch. PAOG management anticipates a lower market entry expense in the targeted international segments. PAOG management also anticipates the international segments to likely contribute a major portion of its overall CBD Nutraceutical sales.
PAOG Introduces International Approach To Targeting $5 Billion CBD Nutraceutical Market
News provided by
Share this article
Share this article
SANDUSKY, Ohio, May 13, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today revealed it will include foreign sales in the planned Q4 launch of its three CBD Nutraceutical Products.
The 2020 CBD Nutraceuticals Market had an estimated value of $5.2 Billion and it is expected to reach $16.4 Billion by 2027.
That market value represents global sales. PAOG management is targeting specific international segments to be included in its Q4 sales launch. PAOG management anticipates a lower market entry expense in the targeted international segments. PAOG management also anticipates the international segments to likely contribute a major portion of its overall CBD Nutraceutical sales.
PAO Group, Inc.: PAOG Confirms CBD Nutraceutical Q4 Revenue Plans
Sandusky, Ohio (Newsfile Corp. - May 11, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to introduce three CBD Nutraceutical Products beginning in the fourth quarter of this year, 2021.
On Friday, PAOG released a preview of the company s plan to launch a CBD Nutraceuticals line of products. PAOG s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments.
PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
PAOG Partners With PURA, ALKM and USMJ To Launch CBD Nutraceutical Product Line
News provided by
Share this article
Share this article
SANDUSKY, Ohio, May 7, 2021 /PRNewswire/ PAO Group, Inc. (USOTC: PAOG) today released a preview of the company s plan to launch a CBD Nutraceuticals line of products. PAOG s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments.
PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
(0)
Sandusky, Ohio (Newsfile Corp. - May 7, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released a preview of the company s plan to launch a CBD Nutraceuticals line of products. PAOG s CBD Nutraceuticals are expected to generate revenue this year, in 2021, while the company continues with its long-term CBD pharmaceutical developments.
PAOG is working on the development of a CBD pharmaceutical product under the name RespRx, for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.
Starting in the fourth quarter of 2021, PAOG plans to begin the introduction of three CBD Nutraceuticals.